Fetal Growth Restriction (FGR), Intrauterine Growth Restriction
Conditions
Keywords
sFlt1, PlGF, IUGR, intrauterine growth restriction, fetal growth restriction
Brief summary
The main aim of this project is to determine the Placental Growth Factor and Vascular Endothelial Growth Factor ratio's performance (sFlt-1/PlGF) for the etiological diagnosis of vascular Intrauterine growth restriction (IUGR) compared to a non-vascular IUGR.
Detailed description
Intra-uterine growth restriction is one of the most frequent cause of consultation in prenatal diagnosis centers. Suspected Intrauterine growth restriction (IUGR) concerns 5.4% of pregnancies. Prognosis and management of IUGR depends on its etiology. It has been estimated that 80 to 90% of IUGR have a vascular cause, 5-15% an infectious cause and 2 to 5% chromosomal or genetic cause. More recently, a meta-analysis has shown that among 874 IUGR fetuses for whom amniocentesis was performed, anomaly of caryotype or comparative genomic hybridization array was reported for 6%. In case of vascular IUGR, amniocentesis is not indicated and close surveillance of mother and fetus is organized. The diagnosis of vascular IUGR is most often confirmed after birth with placental histology. Before birth, the diagnosis of vascular IUGR is presumptive, and based on gestational age at diagnosis, quantity of amniotic fluid, end dopplers of umbilical artery and uterine arteries. The argument considered as most specific of vascular IUGR is the doppler of uterine arteries, however it has been shown that sensitivity of this test is weak : abnormal uterine arteries is reported in only 40% of fetuses with vasculat IUGR according to placenta pathology. Biochemical markers Placental Growth Factor and Vascular Endothelial Growth Factor (sFlt1 and PlGF) have shown their prognostic value on the occurrence of preeclampsia. They are both associated to the delay until occurrence of preeclampsia and to the delay before extraction in case of IUGR. As diagnostic tool in IUGR, only two studies have investigated their value : the PlGF/sFlt-1 ratio identified 7 patients among 10 with abnormal placental pathology, and low PlGF value is associated with abnormal placental pathology among 122 cases of IUGR, however this study did not specify sensitivity and specificity values. A reliable and reproductible marker that could orient practitioners towards the need to propose amniocentesis at diagnosis of IUGR is therefore important to develop. The main objective of ANGIOPAG is to determine the sFlt-1/PlGF ratio's performance for the etiological diagnosis of vascular IUGR compared to a non-vascular IUGR. To reach this goal, ANGIOPAG is a diagnostic, multicenter, non-randomized study. It will be performed on 152 pregnant women over 18 with a term between 22and 34 +6 Weeks of Gestation (WG), consulting in participating centers for IUGR. For the research, a blood test will be carried, at the inclusion and 2 to 4 weeks after, to determine sFLT-1 and PlGF. All included patients'placenta will be analyzed, even in case of a child normal birth weight.
Interventions
BIOLOGICALBlood test at time of inclusion for sFlt-1/PlGF ratio
As part of the research, a blood sample is taken to measure the sFLT-1 and PlGF ratio at the inclusion visit.
BIOLOGICALFollow-up blood test 2 to 4 weeks after inclusion
As part of the research, a blood sample is taken to measure the sFLT-1 and PlGF ratio at the follow-up visit (about 2-4 weeks after inclusion). This second sample is not mandatory for the evaluation of the study's main endpoint.
DIAGNOSTIC_TESTPlacenta analysis for all included patients, even in case of normal birthweight
After delivery, the placenta of each included patient is sent to anatomo-pathology (even in case of normal weight of the baby at birth). An anatomopathologist referent, designated for the study in each center, performs an analysis (aware of the clinic but not of the sFLT-1/PlGF ratio results), according to the benchmark criteria grid. Local analysis will classify the placenta as "vascular IUGR" or "nonvascular IUGR".
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Masking description
Regarding the placenta study : for each patient included, the placenta is sent to anatomo-pathology and a referent anatomo-pathologist designated for the study in each center makes an analysis (blind of dosages of sFlt-1/PlGF but not of the clinic)
Intervention model description
Patients consulting in one of the participating centers for intra uterine growth restriction.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* \> 18 years old * Singleton pregnancy * Date of conception evaluated by ultrasound \< 14 WG * Consulting in one of the 3 participating centers for IUGR * Estimated fetal weight \< 5th centile (according to Hadlock 3 et CFEF) * Between 22+0 WG et 34+6 WG
Exclusion criteria
* Major birth defect diagnosed at time of inclusion * Abnormality of caryotype known at time of inclusion * Confirmed preeclampsia at time of inclusion
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To compare the PlGF / sFlt-1 ratio and placental lesions to confirm the diagnosis of vascular intrauterine growth retardation | 34+6 Weeks of Gestation | The etiological diagnosis will be confirmed as vascular if characteristic lesions are identified on placental analysis. Lesions of maternal vascular malperfusion have been described and are those used in scientific literature. These characteristics are placental infarcts, decidual arteriopathy, and villous hypoplasia. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Delay between inclusion and birth | 21 weeks after inclusion | Delay between inclusion and birth |
| Occurrence of preeclampsia | 21 weeks after inclusion | Occurrence of preeclampsia |
| Gestational age at birth | maximum 21 weeks after inclusion | Gestational age at birth |
| Birth weight | maximum 21 weeks after inclusion | Birth weight |
| Newborn evaluation (presence of birth defects) | maximum 21 weeks after inclusion | Newborn evaluation (presence of birth defects) |
| Rate of transfers to intensive care unit | maximum 21 weeks after inclusion | Rate of transfers to intensive care unit |
| Rate of death of babies | maximum 21 weeks after inclusion | Rate of death of babies |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORJeanne Sibiude, MD, PhD
Assistance Publique - Hôpitaux de Paris
Outcome results
None listed